BioSpace News Archive

LivaNova PLC, a market-leading medical technology and innovation company, reported results for the quarter ended September 30, 2020.

ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, welcomes Dr. David Wishart, Distinguished University Professor in the Departments of Biological Sciences and Computing Science at the University of Alberta, to its Scientific Advisory Board.

IDEXX Laboratories, Inc., a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, announced third quarter results, as well as business and market condition updates related to the 2019 novel coronavirus pandemic.

Trial to study next-generation device as treatment alternative to NOACs for broader population of patients with non-valvular atrial fibrillation

Magellan Health, Inc. announced financial results for the third quarter ended September 30, 2020

Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that it will report third quarter 2020 financial results after market close on Thursday, November 5, 2020

FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2020 financial results on Thursday, November 5 after the market close.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter 2020 on Thursday, November 5, 2020.

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the Company will host a live conference call and audio webcast on Thursday, November 5, 2020 at 4:30 p.m. ET, to discuss its financial results and business highlights for the third quarter ended September 30, 2020.

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today reported financial results and business highlights for the third quarter of 2020.